ライフサイエンスコーパス: cefazolin

1 extended-spectrum prophylaxis (compared with cefazolin).

2 afcillin) or first-generation cephalosporin (cefazolin).

3 or other drug if the patient was allergic to cefazolin).

4 os below the null, except for vancomycin vs. cefazolin.

5 is resistant to ampicillin, ticarcillin, and cefazolin.

6 ents and surgical site infection compared to cefazolin.

7 reated with antistaphylococcal penicillin or cefazolin.

8 ively assessed surgical patients allergic to cefazolin.

9 enicillin allergy history may safely receive cefazolin.

10 %-3.3%; I2 = 85.5%) had confirmed allergy to cefazolin.

11 %) patients received definitive therapy with cefazolin.

12 r patients requiring a prolonged duration of cefazolin.

13 BU2 killing compared to decreased killing by cefazolin.

14 ntravenous antibiotic prophylaxis, primarily cefazolin.

15 ecifically antistaphylococcal penicillins or cefazolin.

16 tively, for those treated with nafcillin and cefazolin.

17 ains and maintain sterility after removal of cefazolin.

18 incubation at 37 degrees C in the absence of cefazolin.

19 ic acid and a first-generation cephalosporin cefazolin.

20 who receive a beta-lactam antibiotic such as cefazolin.

21 6.7% of outpatients with MSSA were receiving cefazolin.

22 ted with cellular response to the antibiotic Cefazolin.

23 coli cells to penicillin G-streptomycin and cefazolin.

24 potentiated the benefit of prophylaxis with cefazolin.

25 llergy who had been exposed to perioperative cefazolin (0.1%; 95% CrI, 0.1%-0.3%; I2 = 13.1%).

26 An intracameral bolus injection of cefazolin (1 mg in 0.1 ml solution) at the conclusion of

27 There were 3 very major errors (all with cefazolin), 1 major error (also with cefazolin), and 26

28 ceived ASP (22.9% versus 24.1%, P = 0.86) or cefazolin (10.3% versus 11.9%, P = 0.86).

29 ed and received a single intravenous dose of cefazolin (15 mg/kg) and tobramycin (0.6 mg/kg).

30 r PD-related peritonitis may be adequate for cefazolin (15 to 20 mg/kg); however, tobramycin doses mu

31 y Standards Institute: gentamicin, 4 mug/mL; cefazolin, 2 mug/mL; and vancomycin, 2 mug/mL.

32 e to all antimicrobial agents tested, except cefazolin (20% of isolates were resistant) and cefoxitin

33 zolin compared to WT bacteremia treated with cefazolin (20%).

34 a 0.5 cc subconjunctival injection of a 1:1 Cefazolin (50 mg/cc):Dexamethasone (10 mg/cc) in the inf

35 3.6%) (p < 0.0001) in the Spanish cohort and cefazolin (51%) (p < 0.0001) in the Italian one.

36 likelihood of coverage was ampicillin 31.8%, cefazolin 62.7%, ceftriaxone 67.1%, piperacillin-tazobac

37 tistaphylococcal penicillin (139 [64.4%]) or cefazolin (77 [35.6%]).

38 CA was lower for ampicillin (80.3%) and cefazolin (77.0%).

39 ptible E. coli UTI, subsequent recovery of a cefazolin (8%) or ampicillin (13%) -resistant isolate du

40 In murine kidneys, administration of cefazolin, a commonly used perioperative antibiotic, led

41 agent were associated with fewer SSI events (cefazolin: adjusted OR = 0.49; 95% CI, 0.34-0.71; quinol

42 ify the percentage of patients who completed cefazolin after experiencing a suspected non-IgE-mediate

43 Treatment with cefazolin after experiencing a suspected non-IgE-mediate

44 a are needed to evaluate the tolerability of cefazolin after switching from nafcillin.

45 Eight patients (10%) did not tolerate cefazolin after switching from nafcillin.

46 in discontinuation, treatment was changed to cefazolin; all 9 completed treatment with no further obs

47 nnovative method to reproducibly distinguish cefazolin-allergic from nonallergic patients using finel

48 drug allergy-negative control patients, or 2 cefazolin-allergic patients who provided 3 samples.

49 s that can effectively diagnose IgE-mediated cefazolin allergy in patients.

50 Cefazolin allergy was identified in 44 participants with

51 nfirmed in 16 participants with a history of cefazolin allergy, resulting in a meta-analytical freque

52 njury (AKI) compared with patients receiving cefazolin alone (aOR: 1.19; 95% CI: 1.11-1.27; P < .001)

53 spectrum SSI prophylaxis with ceftriaxone or cefazolin alone was administered in 488 of 577 patients

54 ociated with superior outcomes compared with cefazolin alone.

55 t intraperitoneal administration of 15 mg/kg cefazolin and 0.6 mg/kg tobramycin.

56 Dual allergy to cefazolin and a natural penicillin.

57 reonam, cefepime, and ceftriaxone, and 1 for cefazolin and ceftazidime).

58 Cefazolin and ertapenem combination therapy was used suc

59 The combination of cefazolin and ertapenem provides potent in vivo activity

60 oxifloxacin alone, 20.8% receiving fortified cefazolin and fortified tobramycin together, and 12.5% r

61 rioperative prophylaxis included vancomycin, cefazolin and micafungin and was adjusted based on perit

62 are less likely to prophylactically receive cefazolin and more likely to receive clindamycin or vanc

63 presence of blaZ and for inoculum effects to cefazolin and oxacillin.

64 ved in the presence of all concentrations of cefazolin and piperacillin-tazobactam.

65 o other antibiotics, there was resistance to cefazolin and sensitivity to vancomycin in all isolates,

66 ncubation at 28 degrees C in the presence of cefazolin and subsequent incubation at 37 degrees C in t

67 ates were similar between children receiving cefazolin and those receiving more extended-spectrum ant

68 Cefazolin and tobramycin half-lives were markedly differ

69 that of combination therapy using fortified cefazolin and tobramycin in the treatment of moderate ba

70 The disposition of intravenous cefazolin and tobramycin was studied in automated PD (AP

71 included patients who had index allergies to cefazolin and were tested for tolerability to a natural

72 05%) observed using the Vitek 2 breakpoints (cefazolin) and 8 VMEs (0.5%) using the CLSI breakpoints

73 ll with cefazolin), 1 major error (also with cefazolin), and 26 minor errors.

74 ith 160 mug/mL of gentamicin, 2000 mug/mL of cefazolin, and 2000 mug/mL of vancomycin in a 200-mL sal

75 llenges with cefuroxime axetil, ceftriaxone, cefazolin, and ceftibuten; and group C and D subjects un

76 subjects underwent challenges with cefaclor, cefazolin, and ceftibuten; group B participants underwen

77 solates (49%) were sensitive to cephalothin, cefazolin, and cefuroxime.

78 ly important cephalosporins, ceftriaxone and cefazolin, and evaluated the binding of cephalosporin to

79 mized to receive locally applied gentamicin, cefazolin, and vancomycin or placebo.

80 ith a Solution of Gentamicin, Vancomycin and Cefazolin Antibiotics for Women Undergoing Breast Recons

81 Nafcillin and cefazolin are considered first-line therapy for most inf

82 on is that antistaphylococcal penicillin and cefazolin are equally effective in treating methicillin-

83 Antistaphylococcal penicillins (ASP) and cefazolin are first-line treatment of methicillin-suscep

84 Multiple forms of cefazolin are immunogenic when multivalently presented b

85 t-line MSSA therapies (nafcillin, oxacillin, cefazolin) are generally avoided in the 10% of patients

86 g penicillin-G, amoxicillin, ampicillin, and cefazolin, are protected from beta-lactamase hydrolysis

87 reus strains were exposed to ceftriaxone and cefazolin at concentrations from 0 to 1000 mug/mL under

88 The Raman spectra of cells exposed to Cefazolin at the end of log phase exhibited a different

89 Cefazolin-based perioperative antibiotic prophylaxis is

90 these findings, we recommend that high-dose cefazolin be used for prophylaxis in (sub)normothermic o

91 d non-IgE-mediated HSR, and were switched to cefazolin between October 2015 and November 2019 at a si

92 Ceftriaxone and cefazolin bind to subdomain IB of HSA, and their cephem

93 preoperative intravenous dose of 1000 mg of cefazolin (cefazolin group, n = 228) or sodium chloride

94 Aztreonam, cefazolin, cefepime, and, to a lesser extent, ceftazidim

95 (MICs) of four antimicrobial agents, namely, cefazolin, ceftazidime, cefepime, and doripenem, were de

96 Polymyxin B was studied in combination with cefazolin, ceftriaxone, cefepime, imipenem, gentamicin,

97 A total of 264 isolates were subjected to cefazolin, ceftriaxone, cefotaxime, ceftazidime, cefepim

98 uency (pdf) and cell length of GNB under the cefazolin (CEZ) treatment.

99 ), benzylpenicillin (PEG), cephalexin (CFX), cefazolin (CFL), cefoperazone (CFP), cloxacillin (CLO),

100 Cefazolin (CFZ) and cephapirin (CFP) underwent mainly di

101 P), trimethoprim-sulfamethoxazole (SXT), and cefazolin (CFZ) susceptibilities were <71%.

102 cteriaceae for susceptibility to ampicillin, cefazolin, ciprofloxacin, colistin, gentamicin, meropene

103 illin, clindamycin, amoxicillin/clavulanate, cefazolin, ciprofloxacin, metronidazole, and paclitaxel.

104 increased survival (100%) when treated with cefazolin compared to WT bacteremia treated with cefazol

105 36) were similar among patients who received cefazolin compared with patients who received nafcillin

106 e, a single preoperative dose of intravenous cefazolin compared with saline did not reduce the risk o

107 g PS with 10 colony-forming units/mL, only a cefazolin concentration of 1000 mug/mL was able to exert

108 cal infecting organisms; however, the LTC of cefazolin during arthroplasty is poorly understood.

109 Cefazolin exhibited greater bactericidal effect on S. ep

110 of patients treated with either nafcillin or cefazolin for MSSA infection in the outpatient parentera

111 seven years using prophylactic intracameral cefazolin for the prevention of endophthalmitis in catar

112 cians might consider definitive therapy with cefazolin for these infections.

113 beta-lactam (either nafcillin, oxacillin, or cefazolin) for staphylococcal bacteremia may improve inf

114 d an SSI (14.0%): 30 patients (13.2%) in the cefazolin group vs 36 in the saline group (14.9%) (absol

115 ve intravenous dose of 1000 mg of cefazolin (cefazolin group, n = 228) or sodium chloride (0.9%; sali

116 The hazard ratio for PAD in the nafcillin vs cefazolin groups was 2.81 (95% confidence interval [CI],

117 Patients who received cefazolin had a 37% reduction in 30-day mortality (hazar

118 ge, multicenter study, patients who received cefazolin had a lower risk of mortality and similar odds

119 from nonallergic patients using finely tuned cefazolin-hapten-presenting nanoallergens in conjunction

120 history excludes anaphylactic features, give cefazolin (Hx-Cefaz); and (3) complete allergy evaluatio

121 ternative cephalosporins (ceftibuten in 101, cefazolin in 96, cefaclor in 82, and cefuroxime axetil a

122 eased antibiotic tolerance to vancomycin and cefazolin in comparison to WT and complement biofilms.

123 is study was to describe the tolerability of cefazolin in patients who develop a suspected non-IgE-me

124 hout a tourniquet, the mean concentration of cefazolin in serum was 71.9 mug/mL (95% CI, 66.4-77.5 mu

125 with a tourniquet, the mean concentration of cefazolin in serum was 72.0 mug/mL (95% CI, 66.3-77.7 mu

126 ficantly lower mean LTCs by 60 minutes after cefazolin infusion (10.8 mug/g [95% CI, 9.1-12.4 mug/g]

127 thalmitis reduced from 0.63% to 0.05% with a cefazolin injection.

128 The cefazolin inoculum effect (CzIE) causes the cefazolin MI

129 The cefazolin inoculum effect (CzIE) has been associated wit

130 revisited this practice and determined that cefazolin is a more accurate proxy than cephalothin for

131 Although cefazolin is an attractive therapeutic alternative in me

132 Cefazolin is the preoperative antibiotic of choice becau

133 ived intravenous antibiotics (ciprofloxacin, cefazolin, later switched to cloxacillin) for one month

134 en exposed to meropenem, imipenem, cefepime, cefazolin, levofloxacin, and piperacillin-tazobactam in

135 entrations of meropenem, imipenem, cefepime, cefazolin, levofloxacin, and piperacillin-tazobactam on

136 y associated with lower SSI rates, including cefazolin/metronidazole, ciprofloxacin/metronidazole, an

137 The cefazolin MIC determination at a high inoculum (10(7) CF

138 cefazolin inoculum effect (CzIE) causes the cefazolin MIC to be elevated in proportion to the number

139 itive isolates (29.8%) had standard inoculum cefazolin MICs of 1.0 mug/mL than the CzIE-negative isol

140 e valve endocarditis is based on cloxacillin/cefazolin monotherapy.

141 (intravenous flucloxacillin, cloxacillin, or cefazolin) (n = 174) or standard therapy alone (n = 178)

142 or MSSA and received definitive therapy with cefazolin, nafcillin, or oxacillin.

143 was associated with duration of exposure to cefazolin (odds ratio, 10.3; p < or = .006) and to broad

144 ler (cefazolin on cycler : 10.67 +/- 4.66 h; cefazolin off cycler : 23.09 +/- 5.6 h; P = 0.001; tobra

145 arkedly different on cycler than off cycler (cefazolin on cycler : 10.67 +/- 4.66 h; cefazolin off cy

146 ities are known, MSSA should be treated with cefazolin or an antistaphylococcal penicillin.

147 ks of standard intravenous therapy (n = 100; cefazolin or antistaphylococcal penicillin if methicilli

148 decreased further for patients who received cefazolin or antistaphylococcal penicillins compared wit

149 Cefazolin or antistaphylococcal penicillins should be us

150 l data exists on the comparative efficacy of cefazolin or ASP in qualitatively susceptible strains th

151 munity-acquired MSSA bacteremia treated with cefazolin or ASP, stratified by oxacillin MIC.

152 MRSA carriers received vancomycin and cefazolin or cefuroxime for perioperative prophylaxis; a

153 tive prophylactic intravenous cephalosporin (cefazolin or cefuroxime) that began within 8 hours after

154 rioperative prophylaxis; all others received cefazolin or cefuroxime.

155 tment with daptomycin when given with either cefazolin or cloxacillin for the treatment of MSSA BSI.

156 aged 18 years with MSSA BSI receiving either cefazolin or cloxacillin monotherapy were considered for

157 nicillin and were tested for tolerability to cefazolin or that included patients who had index allerg

158 a beta-lactam (n = 24), including oxacillin, cefazolin, or ceftaroline, or a glyco-/lipopeptide (n =

159 r a beta-lactam (n=24), including oxacillin, cefazolin, or ceftaroline, or a glyco-/lipopeptide (n=35

160 microbial resistance over time was observed: cefazolin (P = 0.02), cefotetan (P = 0.006), cephalothin

161 .02] vs 3.7 days [95% CI, 2.2-5.2 days] for cefazolin [P = .002]).

162 ed treatment course with nafcillin than with cefazolin (PAD rate, 33.8% vs 6.7%; P < .0001).

163 robial metabolite of ceftiofur), ampicillin, cefazolin, penicillin G, oxacillin, cloxacillin, naficil

164 While in vitro synergy was modest, cefazolin plus ertapenem exhibited synergistic action in

165 rocedure characteristics, patients receiving cefazolin plus vancomycin had 19% higher odds of acute k

166 ith wound infections complicating the use of cefazolin prophylaxis in surgery.

167 ge of the 120 wound isolates associated with cefazolin prophylaxis than they did of the 95 isolates a

168 for the beta-lactamase-negative isolate when cefazolin prophylaxis was administered (599 vs. 128 cfu,

169 The addition of vancomycin to cefazolin prophylaxis was not superior to placebo for th

170 cin or normal saline placebo, in addition to cefazolin prophylaxis.

171 Model-predicted intraperitoneal cefazolin provides adequate serum and dialysate concentr

172 the current prophylactic dosing regimen for cefazolin provides sufficient serum concentrations, the

173 The primary outcome was the LTC of cefazolin, quantified using the liquid chromatography-ta

174 Antistaphylococcal penicillins and cefazolin remain the primary treatments for infections w

175 Vancomycin and cefazolin remained above the MIC for S aureus significan

176 on between the outer membrane porin nmpC and cefazolin resistance in E. coli.

177 Cefazolin resistance ranged from 17% of A. veronii bioty

178 bilty testing, all Enterococci isolates were cefazolin-resistant.

179 119 patients were treated with nafcillin or cefazolin, respectively.

180 Finally, 1000 mug/mL cefazolin showed no adverse effects on porcine kidney en

181 preoperative antibacterial prophylaxis with cefazolin sodium (or other drug if the patient was aller

182 p A was given combination therapy (fortified cefazolin sodium 5% and tobramycin sulfate) and group B

183 Cefazolin sodium and quinolone in combination with an an

184 titutions A, B, and C were cefoxitin sodium, cefazolin sodium with metronidazole, and ampicillin sodi

185 egative controls and were compared against a cefazolin-specific monoclonal IgE.

186 CN skin testing: if skin test negative, give cefazolin (ST-Cefaz).

187 Therefore, a cefazolin surrogacy breakpoint was established to predic

188 operational challenges when implementing the cefazolin surrogacy breakpoint, which may lead to confus

189 For the very hydrophilic cefazolin there was little sign of efflux.

190 dy aimed to identify immunogenic moieties of cefazolin to accurately predict IgE-mediated allergy and

191 One patient was ultimately switched from cefazolin to daptomycin due to concern for treatment fai

192 categories, ranging from narrow (category 1: cefazolin), to broad).

193 es of both PAD as well as DEEs compared with cefazolin treatment.

194 Cefazolin use in prophylaxis is a risk factor for BSSA-5

195 nced and sustained increase in perioperative cefazolin use.

196 This study compared definitive therapy with cefazolin vs nafcillin or oxacillin among patients with

197 nts from 100 hospitals in the United States, cefazolin was 9-fold less likely to be used in patients

198 The toxicity of cefazolin was assessed by cell viability and caspase act

199 week after blood culture collection, use of cefazolin was associated with a 38% lower risk for hospi

200 Only cefazolin was detectable in blood samples, albeit in ver

201 o mimic procedural conditions, the effect of cefazolin was determined after exposure of bacteria to 2

202 In vitro assays demonstrated that cefazolin was hydrolyzed faster by BSSA-5 strains than b

203 09 (in whom a 1 mg/0.1 bolus of intracameral cefazolin was instilled).

204 domized clinical trial, the concentration of cefazolin was lower in local tissues (fat, synovium, and

205 Cefazolin was the most commonly used antibiotic (69.2%),

206 pe A BlaZ (the most efficient enzyme against cefazolin) was 92.7% with a specificity of 87.8%.

207 Seventy-one (89%) patients completed cefazolin, with 53 (75%) of these patients completing at

208 was attributed to nafcillin and discontinued cefazolin within 7 days.